Pancreatic cancer has long been oncology’s most stubborn adversary. Fewer than 13% of patients survive five years after ...

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but ...

The TroFuse-005 trial involved 776 patients with endometrial cancer whose disease worsened after receiving both platinum ...

The presentations will include updated clinical data from the phase 1A/B study of AB248, Asher Bio’s investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, alone and in combination ...

Uterine cancer is the deadliest cancer of the female reproductive system. Currently, clinicians treat the disease by using a ...

NICE has recommended a new treatment option for adults with recurrent or metastatic cervical cancer that has progressed on or ...

Novel approaches in molecular imaging and targeted therapeutics are transforming the management of renal cell carcinoma (RCC) and urothelial carcinoma (UC). This review focuses on three key areas of ...

Roche’s Genentech unit is emphasizing next-generation breast cancer therapies, targeted oncology combinations and brain-penetrating treatments at ASCO 2026. Key Investor Takeaways ・Genentech, part of ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other ...

Zymeworks Inc. announced that their bispecific antibody, zanidatamab, has received conditional approval from China's National Medical Products Administration (NMPA) for treating previously treated, ...